Using high-throughput sequencing (NGS), mass spectrometry, and qPCR-based assays, OHMX.bio identifies and validates predictive biomarkers that correlate with drug efficacy and patient response.
OHMX.bio ensures the highest assay sensitivity, specificity, and reproducibility, optimizing analytical parameters for regulatory approval.
Comprehensive genomic profiling for predictive and prognostic biomarker identification.
High-precision protein biomarker quantification for drug-response analysis.
Sensitive and rapid detection of actionable genetic variants.
Functional validation of biomarkers in patient-derived samples.
Process raw sequencing data, perform quality control, and conduct differential analysis to pinpoint significant biomarkers.
Combine genomic, epigenetic, and transcriptomic information to build a comprehensive biological picture, increasing the predictive power of the biomarker signature.
